anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a hair tonic, containing an extract of a ginkgo and mucopolysaccharides and capable of accelerating and normalizing hair and scalp function and providing excellent hair tonic and growth effects. CONSTITUTION:A hair tonic containing (A) an extract obtained by extracting a leaf, flower, branch, fruit, etc., of a ginkgo with an aqueous solution of preferably an organic solvent miscible with water (especially ethyl alcohol, methyl alcohol, acetone, etc.) and (B) mucopolysaccharides, especially hyaluronic acid, chondroitin sulfate and salts thereof. The aforementioned ingredients are contained in the following amounts (expressed in terms of dried solid content). 0.0001-10wt.%, especially 0.01-5wt.% ingredient (A) and 0.0001-5wt.%. especially 0.001-3wt.% ingredient (B).
PURPOSE: Provided is an active fraction for the prevention and treatment of obesity in Leprdb/Leprdb mice. The composition is isolated from galenical. Also, provided are a method for extracting and purifying the active fraction and galenical containing it as an active ingredient for the prevention and treatment of obesity. CONSTITUTION: The active fraction for the prevention and treatment of obesity is obtained from Adenophora triphylla var. japonica Hara. The composition for the prevention and treatment of obesity contains a therapeutically or prophylactically effective amount of the active fraction as a main ingredient. It further contains at least one of pharmaceutically acceptable carriers or excipients.
Participants meeting all study entry criteria who are allocated to the intervention group will also be asked to complete the three study questionnaires. Having completed the questionnaires they will receive the medicines optimisation intervention by the clinical pharmacist. They will be asked to return for repeat appointments with the clinical pharmacist at 2 and 4 months and will be advised that they will be asked to complete the study questionnaires again at the end of the study (at home, via post at 6 months).
The present invention concerns a process for producing refined avocado oil rich in triglycerides. The invention also pertains to refined avocado oil rich in triglycerides obtainable by said process. Advantageously, the refined avocado oil of the invention contains a sterols-enriched unsaponifiable fraction. Advantageously, the refined avocado oil of the invention is substantially free of acetogenins and furanic lipids. The invention also concerns compositions containing said oil. The invention also pertains to such compositions for use as a medication, as a dermatological agent, as a cosmetic agent, or as a nutriceutical, for human or animal use.
NEW MATERIAL:A compound expressed by formula I (R is H, hydroxymethyl or carboxyl; n is an integer 0 or 1), ester and salt thereof. EXAMPLE:beta-( 2,3-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-H-benzopyran-2-y l)alanine hydrochloride. USE:An analgesic agent, having better analgesic action than aspirin with high safety. The agent is administered particularly preferably by oral routes or intravenous injection, and the dose thereof is preferably 100-500mg/day for adults. PREPARATION:An aldehyde expressed by formula II (R' is H or protecting group of OH) is reacted with ammonium carbonate and an alkali metal cyanide, e.g. sodium cyanide, to give a hydantoin expressed by formula III, which is then hydrolyzed to afford the aimed compound expressed by formula I (R is COOH).
<P>PROBLEM TO BE SOLVED: To enable work management in a dispensing pharmacy as using a picking inspection system enabling job tracking from the viewpoint of dispensing error prevention.  <P>SOLUTION: A worker in charge inputs contents described on a received prescription into a computer 1 (S2), and another person (worker) in charge checks the input data against the contents of the prescription (prescription input check) (S3). A picking job is then performed (S4). A worker such as a pharmacist in charge checks the picking to reveal whether picked medicine names and amounts are correct or not (S5). Administration guidance is then given (S6). The inputs can be either an information terminal such as a handy terminal 5 or the computer 1. Job content and input time data, which are stored as work history data for every input, are used in work management in a dispensing pharmacy.  <P>COPYRIGHT: (C)2004,JPO
PROBLEM TO BE SOLVED: To prepare a cosmetic, having suppressed solid acid and photocatalytic activities, better in safety and excellent in touch and ultraviolet light protecting effects by formulating a zinc oxide powder subjected to a specific treatment therein. SOLUTION: This cosmetic is prepared by formulating an activity-suppressed type zinc oxide powder obtained by heat-treating a zinc oxide powder at 600-1,700 deg.C, preferably 800-1,200 deg.C therein. The average primary particle diameter of the zinc oxide powder used as a raw material is preferably 5nm to 100μm. Besides a compound purely represented by ZnO, a powder having the surface coated with zinc oxide, e.g. a titanium oxide powder treated by coating thereof with the zinc oxide may be used as the zinc oxide powder. One or more ingredients selected from the group of an inorganic and/or an organic ultraviolet light protectants, an antioxidant and a radical scavenger may further be formulated in the cosmetic. The amount of the formulated activity-suppressed type zinc oxide powder in the cosmetic is 0.1-100 pts.wt. based on 100 pts.wt. cosmetic.
Day-to-day positioning variations contribute to uncertainty in radiotherapy. The International Commission on Radiation Units and Measurements (ICRU) report 62 recommended a margin added to the clinical target volume (CTV) to produce the planning target volume (PTV). In ICRU report 83, this concept is further extended and refined to yield the internal target volume (ITV), which is defined as CTV plus a margin to account for uncertainty within the patient. Image-guided radiotherapy (IGRT) has been developed as a method to lower the margin required in PTV expansion. In current practice, IGRT methods mostly rely on bony anatomy alignment. Due to its nature, internal organ motion cannot be compensated by IGRT. Therefore, an ITV expansion is still required. The optimal ITV expansion margin depends on the magnitude of internal organ motion; the smallest margin that provides adequate coverage is preferred.

In this study, we aim to quantify organ motion of the sigmoid colon anastomosis site during radiotherapy treatment, including movement between fractions (interfraction) and movement within the same fraction (intrafraction).
Participants will apply ruxolitinib 1.5% cream BID through Week 4 to all pruriginous lesions. At Week 4, participants who have completed 4 weeks of treatment with no safety concerns may enter the optional 4-week treatment extension period, during which all participants will apply ruxolitinib 1.5% cream BID to existing pruriginous lesions.
Perilla meal hydrolysates (PMHs) were prepared by proteases; volatile profiles from heated mixtures of PMH and coconut oil (CO) were evaluated for their application as odor providers. Amino acids composition and degree of hydrolysis, and antioxidant activity in O/W emulsion of PMHs were assessed. PMHs were heated with different concentration of CO or with CO, xylose, and cysteine, which were non-Maillard and Maillard system, respectively. Among PMHs, double enzyme treatment using Alcalase and Flavourzyme showed higher degree of hydrolysis and antioxidant activity compared to PMHs from one type of enzymes. The presence of CO significantly increased oxygen, sulfur, and nitrogen-containing volatiles from PMHs in non-Maillard system. In case of Maillard system, PMHs with 10 % (w/w) CO contributed the formation of oxygen and nitrogen-containing volatiles such as furan and 2-methylpyrazine. PMHs might serve as an odor generator in the presence of edible oils like CO.
NEW MATERIAL:An angelic ester derivative shown by the formula (R is n- hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, cyclopentyl, cylohexyl, 2-methylpentyl, alpha-methylbenzyl, furfuryl, or neryl). EXAMPLE:Heptyl angelate. USE:Useful as one component for perfume compositions. The addition of the titled compound to another perfume composition provides further improved effect, it is added to cosmetic, detergent, etc. and usable as a perfume composition for cosmetic. It is added to foods, favorite foods, drinks, etc. and usable as flavor. PROCESS:A mixture of algelic methyl ester and an alcohol corresponding to a compound shown by the formula, namely, n-hexyl alcohol, n-heptyl alcohol, etc. is treated in the presence of an ester exchange catalyst, to give the compound shown by the formula.
OBJECTIVES: Single-sided deafness (SSD) can have consequences for a child's language, educational, and social development. A cochlear implant (CI) is the only device which can restore true binaural hearing, yet they are only approved for children with (SSD) over the age of five in the United States. Reports on speech perception outcomes for children implanted at a younger age are limited. The present study aims to examine the effects of age at implantation, duration of deafness, hearing loss etiology, and presence of additional disabilities on device usage and speech perception outcomes.
METHODS: A retrospective chart review was used to examine demographics and speech perception outcomes for 18 children implanted at age five or younger.
RESULTS: Speech perception results were highly variable, with some children deriving significant benefit and others demonstrating no sound awareness through the implant alone. Age at implantation and duration of deafness did not have a clear impact on outcomes. Device usage was low in many children, often those with anatomical abnormalities such as a hypoplastic cochlear nerve. There are challenges to assessing speech perception in young children with SSD, leading to a lack of standardized outcome measures.
CONCLUSIONS: Early CI for children with SSD may improve speech perception, but benefit is not guaranteed. Candidacy evaluation should consider both medical and audiological factors, in addition to the degree of family support and realistic expectations. Caution is especially warranted in children with significant anatomical anomalies.
Participants receive sorafenib PO on days 1-28, and nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course will continue until 1 dose-limiting toxicity occurs to establish maximum tolerated dose.
UNLABELLED: Ventricular assist device (VAD) infections are frequent causes of hospital readmission. The risk factors and optimal preventive strategies for such, including chronic suppressive antibiotics (CSA), remain uncertain. We performed a single-center, retrospective, observational cohort study assessing continuous flow VAD recipients who underwent implantation between 2008 and 2018 in Japan. From primary VAD infection (VADI), we followed the patients for recurrent infection, defined as relapsing VAD-specific (e.g., localized infections) or VAD-related (e.g., bacteremia) infections requiring hospital readmission. CSA was defined as the use of oral antimicrobial agents continued beyond initial antibiotic use until transplantation, VAD withdrawal, VADI recurrence, or death. Survival analysis was performed to identify risk factors for recurrent infection accounting for competing risks (e.g., deaths and transplants). Among 163 eligible patients, 76 patients had VADIs. The main causative organism in primary VADI was Staphylococcus aureus (63%, 48/76). Among them, 41 had recurrent infections, whereas 35 had none during the follow-up period (median, 335 days). Thirty-six patients received CSA for a median of 478 days. Although CSA was associated with a decreased risk of recurrent infection [adjusted sub-distribution hazard ratio (SHR), 0.40; 95% confidence interval (CI), 0.18-0.89; P = 0.03], this protective effect was observed only after primary VAD-specific infection (SHR, 0.28; 95% CI, 0.12-0.64; P < 0.01) but not after VAD-related infection. Surgical procedures during primary VADI were associated with an increased risk (SHR, 2.00; 95% CI, 1.10-3.66; P = 0.02). One patient had an adverse drug reaction. CSA may be an effective approach to limit relapsing VADIs following a primary VAD-specific infection with minimal adverse events.
IMPORTANCE: Ventricular assist device infections (VADIs) are a significant complication leading to hospital readmissions. However, the risk factors and optimal preventive strategies for VADI remain unclear. This study investigated the effectiveness of chronic suppressive antibiotic therapy in patients with VADI. We found that the use of chronic suppressive antibiotic therapy was associated with a reduction in the risk of VADI recurrence with few adverse reactions. Our findings suggest the potential benefit of chronic suppressive antibiotics in preventing infections in selected cases. Our findings are relevant for the management of patients with ventricular assist devices awaiting heart transplantation, providing valuable insights for clinical practice.
According to an example, a visual call apparatus is described for providing a health care service to a user. The apparatus includes a memory storing machine readable instructions to receive input related to a health related status of a user. The machine readable instructions analyze the health related status of the user to select options, from a plurality of available options, to provide services to the user. The user is to actuate one of the selected options to receive a service related to the actuated option. The machine readable instructions further output the selected options to allow the user to actuate one of the selected options, and upon actuation of one of the selected options, provide feedback to the user related to completion of the service related to the actuated option. The apparatus includes a processor to implement the machine readable instructions.
The present invention relates to supramolecules which are formed by at least two components. Each component comprises an effector molecule and at least one nucleic acid chain. The nucleic acid chains of each component are complementary to nucleic acid chains on other components and thus are able to bind the components of the supramolecule by the formation of double stranded nucleic acid chains between the complementary chains. The present invention also relates to a method of making the supramolecules of the present invention. The nucleic acid chains are preferably DNA, RNA and may also contain structural analogues of DNA or RNA. Effector molecules that may be used to form the supramolecules include, but are not limited to polypeptides, lipids, sugars. These effector molecules may impart chemical, physical properties to the supramolecule that include, but are not limited to hydrophobicity, hydrophilicity, electron conductivity, fluorescence, radioactivity, biological activity, cellular toxicity, catalytic activity, molecular and cellular recognition and in vivo transport selectivity.
BACKGROUND: Despite the important role that cleaning plays in reducing the risk of healthcare-associated infections, no research has been undertaken to quantify the time required for effective cleaning and disinfection of different pieces of shared medical equipment commonly used in hospitals. This short report presents the results from a study that aimed to quantify the time required to clean common pieces of shared medical equipment effectively.
METHODS: An observational time and motion study was conducted in a nursing simulation laboratory to determine the time required for effective cleaning and disinfection of 12 pieces of shared medical equipment commonly used in hospital. After training, the participants cleaned and disinfected equipment, with the time taken to clean recorded. Cleaning was deemed to be effective if ≥80% of ultraviolet fluorescent dots were removed during the cleaning process.
MAIN RESULTS: The time to clean equipment effectively ranged from 50 s [blood glucose testing kit; 95% confidence interval (CI) 0:40-1:00 (min:s)] to 3 min 53 s [medication trolley; 95% CI 3:36-4:11 (min:s)]. The intravenous stand was cleaned most effectively, with 100% of dots removed (N = 100 dots). In contrast, the bladder scanner was the most difficult to clean, with 12 attempts required to meet the 80% threshold for effective cleaning.
CONCLUSION: This study will inform staffing and training requirements to plan the cleaning and disinfection of shared medical equipment effectively. The findings can also be used for business cases, and in future cost-effectiveness evaluations of cleaning interventions that include shared medical equipment.
The invention relates to a method for taking a sample from a system. A user ( 1 ) enters an analysis request to a computer system ( 4 ), whereupon a connection is established between the computer system and a databank. As a result of the analysis request an information catalogue is generated from the databank, from which the at least one sample holder ( 13 ) to be used is suggested or provisionally selected for the user ( 1 ) by means of a input and/or output device ( 5 ). The invention further relates to a method for production of a request data set for a sample for analysis. An information catalogue, corresponding to an entered analysis request is proposed to the user ( 1 ), the data of which from the information catalogue for the entered analysis request may be optionally added to or edited by the user ( 1 ). From said data, test conditions for the sample to be analysed are generated and processed with the holder data, a system identification number and a request number to give a uniform machine-processable request data set which is transmitted to the laboratory ( 2 ) engaged for the above.
Talonavicular (TN) fusion is a common treatment for TN arthritis or deformity correction. There is incongruous evidence regarding remaining motion at the talocalcaneal and calcaneocuboid joints after TN fusion. Additionally, the effects of a malaligned TN fusion are not well understood and alignment of the fusion may be important for overall foot integrity. This project assessed the kinematic and kinetic effects of neutral and malaligned TN fusions. Ten cadaveric feet were tested on a gait simulator in four conditions: unfused, fused in neutral, fused in varus, and fused in valgus. The fusions were simulated with external fixation hardware. An eight-camera motion analysis system and a 10-segment foot model generated kinematic data, and a pressure mat captured pressure data. Simulated TN fusion was achieved in eight feet. From unfused to fused-neutral, range of motion (ROM) was not eliminated in the adjacent joints, but the positions of the joints changed significantly throughout stance phase. Furthermore, the ROM increased at the tibiotalar joint. Plantar pressure and center of pressure shifted laterally with neutral fusion. The malalignments marginally affected the ROM but changed joint positions throughout stance phase. Pressure patterns were shifted laterally in varus malalignment and medially in valgus malalignment. The residual motion and the altered kinematics at the joints in the triple joint complex after TN fusion may subsequently increase the incidence of arthritis. Clinical significance: This study quantifies the effects of talonavicular fusion and malalignment on the other joints of the triple joint complex.
Systems and methods for fitness tracking are provided. A fitness tracking computing system conveys information over a network to a visual display of a device viewable by a user. The device can be a smart phone, tablet computer, or a laptop. Instructions are conveyed to the visual display that identify an exercise to be performed by the user. during performance of the exercise by the user, an exercise status summary is provided to the visual display. Based on the user's movements during performance of the exercise, as tracked by a camera, feedback is provided to the visual display.
PURPOSE: A fusion protein of albumin and retinol binding proteins is provided to induce prevent or treat fibrous diseases in the liver, pancreas, and lung. CONSTITUTION: A fusion protein has albumin and retinol binding proteins(RBP) which are conjugated each other. The albumin includes albumin I domain or albumin III domain. The fusion protein is albumin I domain-RBP-albumin III, albumin III-RBP-albumin I, RBP-albumin III, albumin III RBP, albumin-RPB or RBP-albumin. The fusion protein has one amino acid sequence among sequence numbers 8-13. A polynucleotide encoding the fusion protein has one nucleic acid sequence among sequence numbers 14-19. A medicinal composition for preventing or treating fibrous diseases contains the fusion protein.
A colloidal facial mask with local carrier and a manufacturing method thereof are provided. The colloidal facial mask comprises a colloidal layer and a carrier layer. The colloidal layer is formed by a superabsorbent colloidal film material, such as seaweed gel, polymer gel and biological fiber, for containing a liquid agent such as cosmetic liquid agent, and includes a first surface and a second surface opposite to the first surface, wherein the first surface is utilized to attach on a user's face for allowing the liquid agent contained therein to contact the user's face skin. The carrier layer is connectively attached on at least one local portion of the second surface of the colloidal layer, such as fragile portions including eye portion, nose portion or mouth portion, for reinforcing the mechanical strength of the local portion, but a partial region of the second surface of the colloidal layer is not covered by the carrier layer, thereby reducing the material cost of the carrier layer. The carrier layer is formed of knitted fabric, such as lace cloth, spinning cloth, dobby cloth or nonwoven cloth, for allowing the carrier to have a predetermined pattern or mark in accordance with the requirement. Accordingly, it is able to enhance the appearance decoration effect, brand identification function, usage effect and value for the colloidal facial mask.
The present invention describes peptides capable of specifically binding to preselected micromolecules or to their natural receptor. The preselected molecules include but are not limited to drugs, vitamins, neuromediators and steroid hormones. Methods of using the phage display libraries to identify peptide compositions in preselected binding interactions are also disclosed. The retrieved peptides mimicking a natural receptor binding site to preselected molecules are used as is or as ligands to re-screen the same or different libraries to find and/or derive new receptor ligands, or are used to elicit the production of antibodies capable of binding to the natural receptor. The two categories of effector molecules (peptides or antibodies) may find diagnostic, therapeutic or prophylactic uses. The peptides directly derived from the phage display libraries may be used as drug detectors or antidotes. The others may be used to identify, target, activate or neutralize the receptor for the preselected micromolecules, the receptor being known or unknown.